Literature DB >> 21080788

120 infrabony defects treated with regenerative therapy: long-term results.

Maurizio Silvestri1, Giulio Rasperini, Stefano Milani.   

Abstract

BACKGROUND: The aim of this study is to evaluate the long-term benefits of regenerative therapy and which factors (i.e., smoking, oral hygiene, radiographic angle, tooth, clinical center, and biomaterial) influence results.
METHODS: A total of 120 infrabony defects were treated with guided tissue regeneration using bioabsorbable and non-resorbable membranes with grafts or enamel matrix derivative (EMD) proteins. At baseline, smoking, x-ray angle, probing depth (PD), recession, and clinical attachment level (CAL) were recorded. CAL was measured 1 year post-surgery and every 2 years for ≤16 years. The participation of patients in oral hygiene protocols was recorded.
RESULTS: The mean ± SD baseline CAL was 8.5 ± 2.3 mm, baseline PD was 7.8 ± 2.1 mm, and baseline x-ray angle was 31.8° ± 8.9°. One year post-surgery, CAL gain was 4.1 ± 2.1 mm. EMD was used in 47 defects, bioabsorbable membranes with deproteinized bovine bone were used in 41 cases, non-resorbable membranes were used in seven defects, bioabsorbable membranes and autogenous bone were used in five defects, and a combination was used in 20 defects. A total of 10% of subjects were smokers, and 20% of subjects did not participate in an oral hygiene program. The average follow-up was 9 years. A total of 90% teeth survival was achieved at 13 years, and CAL gain was maintained at 82% for 11 years. Statistical analyses demonstrated that smoking and oral hygiene maintenance influenced long-term outcomes. The x-ray angle, tooth, clinical center, and biomaterials did not influence results.
CONCLUSIONS: Regenerative therapy provided a high percentage of long-term success. Smoking and non-participation in oral hygiene maintenance negatively influenced the prognosis, whereas other factors did not affect long-term results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080788     DOI: 10.1902/jop.2010.100297

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  6 in total

1.  Three-year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a synthetic bone graft.

Authors:  Thomas Hoffmann; Elyan Al-Machot; Jörg Meyle; Pia-Merete Jervøe-Storm; Søren Jepsen
Journal:  Clin Oral Investig       Date:  2015-07-15       Impact factor: 3.573

2.  Treatment of intrabony periodontal defects in controlled diabetic patients with an enamel matrix derivative: a split-mouth randomized clinical trial.

Authors:  Renata Cimões; Leógenes M Santiago; Arnaldo de França Caldas Júnior; Bruna de Carvalho Farias Vajgel; Jeniffer Perussolo; Nikolaos Donos
Journal:  Clin Oral Investig       Date:  2021-10-13       Impact factor: 3.606

3.  Clinical evaluation of the regenerative potential of EMD and NanoHA in periodontal infrabony defects: a 2-year follow-up.

Authors:  Andrea Pilloni; Matteo Saccucci; Gabriele Di Carlo; Blerina Zeza; Marco Ambrosca; Michele Paolantonio; Gilberto Sammartino; Claudio Mongardini; Antonella Polimeni
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

Review 4.  Impact of Orthodontic Treatment on Periodontal Tissues: A Narrative Review of Multidisciplinary Literature.

Authors:  Angelina Gorbunkova; Giorgio Pagni; Anna Brizhak; Giampietro Farronato; Giulio Rasperini
Journal:  Int J Dent       Date:  2016-01-19

5.  Surgical Approaches Based on Biological Objectives: GTR versus GBR Techniques.

Authors:  Gaia Pellegrini; Giorgio Pagni; Giulio Rasperini
Journal:  Int J Dent       Date:  2013-06-13

6.  Long-term clinical outcomes of periodontal regeneration with enamel matrix derivative: A retrospective cohort study with a mean follow-up of 10 years.

Authors:  Siro P De Ry; Andrea Roccuzzo; Niklaus P Lang; Anton Sculean; Giovanni E Salvi
Journal:  J Periodontol       Date:  2021-09-08       Impact factor: 4.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.